Eugen Widmeier1,2, Merlin Airik3, Hannah Hugo1, David Schapiro1, Johannes Wedel1, Chandra C Ghosh1, Makiko Nakayama1, Ronen Schneider1, Agape M Awad4, Anish Nag4, Jang Cho1, Markus Schueler1, Catherine F Clarke4, Rannar Airik5, Friedhelm Hildebrandt6. 1. Division of Nephrology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts. 2. Department of Medicine IV, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. 3. Department of Pediatrics, University of Pittsburgh, Pittsburgh, Pennsylvania; and. 4. Department of Chemistry and Biochemistry and Molecular Biology Institute, University of California, Los Angeles, Los Angeles, California. 5. Department of Pediatrics, University of Pittsburgh, Pittsburgh, Pennsylvania; and Friedhelm.Hildebrandt@childrens.harvard.edu airikr@pitt.edu. 6. Division of Nephrology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts; Friedhelm.Hildebrandt@childrens.harvard.edu airikr@pitt.edu.
Abstract
BACKGROUND: Although studies have identified >55 genes as causing steroid-resistant nephrotic syndrome (SRNS) and localized its pathogenesis to glomerular podocytes, the disease mechanisms of SRNS remain largely enigmatic. We recently reported that individuals with mutations in COQ6, a coenzyme Q (also called CoQ10, CoQ, or ubiquinone) biosynthesis pathway enzyme, develop SRNS with sensorineural deafness, and demonstrated the beneficial effect of CoQ for maintenace of kidney function. METHODS: To study COQ6 function in podocytes, we generated a podocyte-specific Coq6 knockout mouse (Coq6podKO ) model and a transient siRNA-based COQ6 knockdown in a human podocyte cell line. Mice were monitored for development of proteinuria and assessed for development of glomerular sclerosis. Using a podocyte migration assay, we compared motility in COQ6 knockdown podocytes and control podocytes. We also randomly assigned 5-month-old Coq6podKO mice and controls to receive no treatment or 2,4-dihydroxybenzoic acid (2,4-diHB), an analog of a CoQ precursor molecule that is classified as a food additive by health authorities in Europe and the United States. RESULTS: Abrogation of Coq6 in mouse podocytes caused FSGS and proteinuria (>46-fold increases in albuminuria). In vitro studies revealed an impaired podocyte migration rate in COQ6 knockdown human podocytes. Treating Coq6podKO mice or cells with 2,4-diHB prevented renal dysfunction and reversed podocyte migration rate impairment. Survival of Coq6podKO mice given 2,4diHB was comparable to that of control mice and significantly higher than that of untreated Coq6podKO mice, half of which died by 10 months of age. CONCLUSIONS: These findings reveal a potential novel treatment strategy for those cases of human nephrotic syndrome that are caused by a primary dysfunction in the CoQ10 biosynthesis pathway.
BACKGROUND: Although studies have identified >55 genes as causing steroid-resistant nephrotic syndrome (SRNS) and localized its pathogenesis to glomerular podocytes, the disease mechanisms of SRNS remain largely enigmatic. We recently reported that individuals with mutations in COQ6, a coenzyme Q (also called CoQ10, CoQ, or ubiquinone) biosynthesis pathway enzyme, develop SRNS with sensorineural deafness, and demonstrated the beneficial effect of CoQ for maintenace of kidney function. METHODS: To study COQ6 function in podocytes, we generated a podocyte-specific Coq6 knockout mouse (Coq6podKO ) model and a transient siRNA-based COQ6 knockdown in a human podocyte cell line. Mice were monitored for development of proteinuria and assessed for development of glomerular sclerosis. Using a podocyte migration assay, we compared motility in COQ6 knockdown podocytes and control podocytes. We also randomly assigned 5-month-old Coq6podKO mice and controls to receive no treatment or 2,4-dihydroxybenzoic acid (2,4-diHB), an analog of a CoQ precursor molecule that is classified as a food additive by health authorities in Europe and the United States. RESULTS: Abrogation of Coq6 in mouse podocytes caused FSGS and proteinuria (>46-fold increases in albuminuria). In vitro studies revealed an impaired podocyte migration rate in COQ6 knockdown human podocytes. Treating Coq6podKO mice or cells with 2,4-diHB prevented renal dysfunction and reversed podocyte migration rate impairment. Survival of Coq6podKO mice given 2,4diHB was comparable to that of control mice and significantly higher than that of untreated Coq6podKO mice, half of which died by 10 months of age. CONCLUSIONS: These findings reveal a potential novel treatment strategy for those cases of humannephrotic syndrome that are caused by a primary dysfunction in the CoQ10 biosynthesis pathway.
Authors: Moin A Saleem; Michael J O'Hare; Jochen Reiser; Richard J Coward; Carol D Inward; Timothy Farren; Chang Ying Xing; Lan Ni; Peter W Mathieson; Peter Mundel Journal: J Am Soc Nephrol Date: 2002-03 Impact factor: 10.121
Authors: J M Kaplan; S H Kim; K N North; H Rennke; L A Correia; H Q Tong; B J Mathis; J C Rodríguez-Pérez; P G Allen; A H Beggs; M R Pollak Journal: Nat Genet Date: 2000-03 Impact factor: 38.330
Authors: K E Heath; A Campos-Barros; A Toren; G Rozenfeld-Granot; L E Carlsson; J Savige; J C Denison; M C Gregory; J G White; D F Barker; A Greinacher; C J Epstein; M J Glucksman; J A Martignetti Journal: Am J Hum Genet Date: 2001-10-04 Impact factor: 11.025
Authors: A Rötig; E L Appelkvist; V Geromel; D Chretien; N Kadhom; P Edery; M Lebideau; G Dallner; A Munnich; L Ernster; P Rustin Journal: Lancet Date: 2000-07-29 Impact factor: 79.321
Authors: Eriene-Heidi Sidhom; Choah Kim; Maria Kost-Alimova; May Theng Ting; Keith Keller; Julian Avila-Pacheco; Andrew Jb Watts; Katherine A Vernon; Jamie L Marshall; Estefanía Reyes-Bricio; Matthew Racette; Nicolas Wieder; Giulio Kleiner; Elizabeth J Grinkevich; Fei Chen; Astrid Weins; Clary B Clish; Jillian L Shaw; Catarina M Quinzii; Anna Greka Journal: J Clin Invest Date: 2021-03-01 Impact factor: 14.808
Authors: Brian J Shayota; Nhon T Le; Nasim Bekheirnia; Jill A Rosenfeld; Amy C Goldstein; Michael Moritz; Dennis W Bartholomew; Matthew T Pastore; Fan Xia; Christine Eng; Yaping Yang; Dolores J Lamb; Fernando Scaglia; Michael C Braun; Mir Reza Bekheirnia Journal: Mol Genet Genomic Med Date: 2019-09-30 Impact factor: 2.183